Enrollment factors and bias of disease prevalence estimates in administrative claims data

Annals of Epidemiology

Volumn 25, Issue 7, 2015, Pages 519-525.e2

  Jensen, Elizabeth T ^a   Cook, Suzanne F ^b   Allen, Jeffery K ^b   Logie, John ^b   Brookhart, Maurice Alan ^c   Kappelman, Michael D ^a   Dellon, Evan S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

Administrative claims data; Prevalence; Selection bias

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; BARRETT ESOPHAGUS; CELIAC DISEASE; COHORT ANALYSIS; CROHN DISEASE; CROSS-SECTIONAL STUDY; DATA BASE; EOSINOPHILIC ESOPHAGITIS; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MARKETSCAN CLAIMS DATA; PREVALENCE; PRIORITY JOURNAL; SELECTION BIAS; ULCERATIVE COLITIS; ADOLESCENT; ADULT; CHILD; FEMALE; GASTROINTESTINAL DISEASES; HEALTH SERVICE; INFANT; INSURANCE; MALE; MIDDLE AGED; NEWBORN; PATIENT SELECTION; PRESCHOOL CHILD; STATISTICAL BIAS; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; BIAS (EPIDEMIOLOGY); CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; GASTROINTESTINAL DISEASES; HEALTH SERVICES; HUMANS; INFANT; INFANT, NEWBORN; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; PATIENT SELECTION; PREVALENCE; UNITED STATES; YOUNG ADULT;

EID: 84930044767     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2015.03.008     Document Type: Article

References (15)

1. Li S., Peng Y., Weinhandl E.D., Blaes A.H., Cetin K., Chia V.M., et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol 2012, 4:87-93.
2. Dellon E.S., Jensen E.T., Martin C.F., Shaheen N.J., Kappelman M.D. The prevalence of eosinophilic esophagitis in the United States. Clin Gastroenterol Hepatol 2014, 12(4):589-596.
3. Dufour R., Joshi A.V., Pasquale M.K., Schaaf D., Mardekian J., Andrews G.A., et al. The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations. Pain Pract 2014, 14:E106-E115.
4. Prescott J.D., Factor S., Pill M., Levi G.W. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. JManag Care Pharm 2007, 13:44-52.
5. Kappelman M.D., Moore K.R., Allen J.K., Cook S.F. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 2013, 58:519-525.
6. Khanna R., Madhavan S.S., Bhanegaonkar A., Remick S.C. Prevalence, healthcare utilization, and costs of breast cancer in a state Medicaid fee-for-service program. JWomens Health (Larchmt) 2011, 20:739-747.
7. Cosmatos I., Matcho A., Weinstein R., Montgomery M.O., Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. JAm Acad Dermatol 2013, 69:819.
8. Gleason P.P., Alexander G.C., Starner C.I., Ritter S.T., Van Houten H.K., Gunderson B.W., et al. Health plan utilization and costs of specialty drugs within 4 chronic conditions. JManag Care Pharm 2013, 19:542-548.
9. Chubak J., Pocobelli G., Weiss N.S. Tradeoffs between accuracy measures forelectronic health care data algorithms. JClin Epidemiol 2012, 65:343-349 e2.
10. Carnahan R.M., Moores K.G. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned. Pharmacoepidemiol Drug Saf 2012, 21(Suppl 1):82-89.
11. Grosse S.D., Boulet S.L., Grant A.M., Hulihan M.M., Faughnan M.E. The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia. Genet Med 2014, 16:33-39.
12. Food and Drug Administration (US). Developing products for rare diseases and conditions. Bethesda, MD: US Department of Health and Human Services. Available from: Accessed January 15, 2015. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm.
13. Rybnicek D.A., Hathorn K.E., Pfaff E.R., Bulsiewicz W.J., Shaheen N.J., Dellon E.S. Administrative coding is specific, but not sensitive, for identifying eosinophilic esophagitis. Dis Esophagus 2014, 27(8):703-708.
14. Amonkar M.M., Kalsekar I.D., Boyer J.G. The economic burden of Barrett's esophagus in a Medicaid population. Ann Pharmacother 2002, 36:605-611.
15. Tanpowpong P., Broder-Fingert S., Obuch J.C., Rahni D.O., Katz A.J., Leffler D.A., et al. Multicenter study on the value of ICD-9-CM codes for case identification of celiac disease. Ann Epidemiol 2013, 23:136-142.